ID   KPCD_HUMAN              Reviewed;         676 AA.
AC   Q05655; B0KZ81; B2R834; Q15144; Q86XJ6;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Protein kinase C delta type;
DE            EC=2.7.11.13 {ECO:0000269|PubMed:18285462};
DE   AltName: Full=Tyrosine-protein kinase PRKCD;
DE            EC=2.7.10.2;
DE   AltName: Full=nPKC-delta;
DE   Contains:
DE     RecName: Full=Protein kinase C delta type regulatory subunit;
DE   Contains:
DE     RecName: Full=Protein kinase C delta type catalytic subunit;
DE     AltName: Full=Sphingosine-dependent protein kinase-1;
DE              Short=SDK1;
GN   Name=PRKCD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SER-375 AND
RP   MET-593.
RC   TISSUE=Liver;
RX   PubMed=8357834; DOI=10.1016/0167-4781(93)90111-P;
RA   Aris J.P., Basta P.V., Holmes W.D., Ballas L.M., Moomaw C.,
RA   Rankl N.B., Blobel G., Loomis C.R., Burns D.J.;
RT   "Molecular and biochemical characterization of a recombinant human
RT   PKC-delta family member.";
RL   Biochim. Biophys. Acta 1174:171-181(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-365 (ISOFORM 1).
RC   TISSUE=Hippocampus;
RA   Hug H.;
RT   "Partial cDNA Sequence of human protein kinase C delta.";
RL   Submitted (MAR-1993) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 51-676 (ISOFORM 1).
RX   PubMed=9427282; DOI=10.1046/j.1365-2443.1997.1470346.x;
RA   Nomoto S., Watanabe Y., Ninomiya-Tsuji J., Yang L.-X., Kikuchi K.,
RA   Hagiwara M., Hidaka H., Matsumoto K., Irie K.;
RT   "Functional analyses of mammalian protein kinase C isozymes in budding
RT   yeast and mammalian fibroblasts.";
RL   Genes Cells 2:601-614(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 224-371 (ISOFORM 2).
RX   PubMed=18092819; DOI=10.1021/bi7019782;
RA   Jiang K., Apostolatos A.H., Ghansah T., Watson J.E., Vickers T.,
RA   Cooper D.R., Epling-Burnette P.K., Patel N.A.;
RT   "Identification of a novel antiapoptotic human protein kinase C delta
RT   isoform, PKCdeltaVIII in NT2 cells.";
RL   Biochemistry 47:787-797(2008).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 432-533 (ISOFORM 1), AND VARIANT
RP   VAL-494.
RX   PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Identification of multiple, novel, protein kinase C-related gene
RT   products.";
RL   FEBS Lett. 356:5-8(1994).
RN   [9]
RP   FUNCTION.
RX   PubMed=11748588; DOI=10.1002/jcp.10022;
RA   Bankers-Fulbright J.L., Kita H., Gleich G.J., O'Grady S.M.;
RT   "Regulation of human eosinophil NADPH oxidase activity: a central role
RT   for PKCdelta.";
RL   J. Cell. Physiol. 189:306-315(2001).
RN   [10]
RP   MUTAGENESIS OF THR-507.
RX   PubMed=11772397;
RA   Liu Y., Graham C., Li A., Fisher R.J., Shaw S.;
RT   "Phosphorylation of the protein kinase C-theta activation loop and
RT   hydrophobic motif regulates its kinase activity, but only activation
RT   loop phosphorylation is critical to in vivo nuclear-factor-kappaB
RT   induction.";
RL   Biochem. J. 361:255-265(2002).
RN   [11]
RP   INTERACTION WITH PDPK1, AND PHOSPHORYLATION.
RX   PubMed=11781095; DOI=10.1021/bi010719z;
RA   Hodgkinson C.P., Sale G.J.;
RT   "Regulation of both PDK1 and the phosphorylation of PKC-zeta and
RT   -delta by a C-terminal PRK2 fragment.";
RL   Biochemistry 41:561-569(2002).
RN   [12]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=11877440; DOI=10.1074/jbc.M200436200;
RA   Ren J., Li Y., Kufe D.;
RT   "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma
RT   antigen in beta-catenin signaling.";
RL   J. Biol. Chem. 277:17616-17622(2002).
RN   [13]
RP   INTERACTION WITH RAD9A.
RX   PubMed=12628935; DOI=10.1093/emboj/cdg134;
RA   Yoshida K., Wang H.-G., Miki Y., Kufe D.;
RT   "Protein kinase Cdelta is responsible for constitutive and DNA damage-
RT   induced phosphorylation of Rad9.";
RL   EMBO J. 22:1431-1441(2003).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-155.
RX   PubMed=15774464; DOI=10.1074/jbc.M501374200;
RA   Okhrimenko H., Lu W., Xiang C., Ju D., Blumberg P.M., Gomel R.,
RA   Kazimirsky G., Brodie C.;
RT   "Roles of tyrosine phosphorylation and cleavage of protein kinase
RT   Cdelta in its protective effect against tumor necrosis factor-related
RT   apoptosis inducing ligand-induced apoptosis.";
RL   J. Biol. Chem. 280:23643-23652(2005).
RN   [15]
RP   FUNCTION IN PLATELET AGGREGATION, AND INTERACTION WITH VASP.
RX   PubMed=16940418; DOI=10.1182/blood-2006-05-023739;
RA   Pula G., Schuh K., Nakayama K., Nakayama K.I., Walter U., Poole A.W.;
RT   "PKCdelta regulates collagen-induced platelet aggregation through
RT   inhibition of VASP-mediated filopodia formation.";
RL   Blood 108:4035-4044(2006).
RN   [16]
RP   PHOSPHORYLATION AT TYR-313 AND TYR-567.
RX   PubMed=17570831; DOI=10.1042/BJ20070244;
RA   Hall K.J., Jones M.L., Poole A.W.;
RT   "Coincident regulation of PKCdelta in human platelets by
RT   phosphorylation of Tyr311 and Tyr565 and phospholipase C signalling.";
RL   Biochem. J. 406:501-509(2007).
RN   [17]
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT SER-299;
RP   SER-302 AND SER-304, AND MUTAGENESIS OF SER-299.
RX   PubMed=17603046; DOI=10.1016/j.febslet.2007.06.035;
RA   Durgan J., Michael N., Totty N., Parker P.J.;
RT   "Novel phosphorylation site markers of protein kinase C delta
RT   activation.";
RL   FEBS Lett. 581:3377-3381(2007).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17579121; DOI=10.1158/1541-7786.MCR-06-0255;
RA   Gomel R., Xiang C., Finniss S., Lee H.K., Lu W., Okhrimenko H.,
RA   Brodie C.;
RT   "The localization of protein kinase Cdelta in different subcellular
RT   sites affects its proapoptotic and antiapoptotic functions and the
RT   activation of distinct downstream signaling pathways.";
RL   Mol. Cancer Res. 5:627-639(2007).
RN   [19]
RP   PHOSPHORYLATION AT THR-50; THR-141; SER-304; THR-451; SER-506; THR-507
RP   AND SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17965192; DOI=10.1110/ps.072874607;
RA   Welman A., Griffiths J.R., Whetton A.D., Dive C.;
RT   "Protein kinase C delta is phosphorylated on five novel Ser/Thr sites
RT   following inducible overexpression in human colorectal cancer cells.";
RL   Protein Sci. 16:2711-2715(2007).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299; TYR-313; SER-503;
RP   SER-654; SER-658 AND SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=18285462; DOI=10.1128/MCB.01530-07;
RA   Doller A., Akool E.-S., Huwiler A., Mueller R., Radeke H.H.,
RA   Pfeilschifter J., Eberhardt W.;
RT   "Posttranslational modification of the AU-rich element binding protein
RT   HuR by protein kinase Cdelta elicits angiotensin II-induced
RT   stabilization and nuclear export of cyclooxygenase 2 mRNA.";
RL   Mol. Cell. Biol. 28:2608-2625(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130; SER-302; SER-304;
RP   SER-307 AND SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   FUNCTION IN PLATELET RESPONSE.
RX   PubMed=19587372; DOI=10.1182/blood-2008-11-188516;
RA   Chari R., Kim S., Murugappan S., Sanjay A., Daniel J.L.,
RA   Kunapuli S.P.;
RT   "Lyn, PKC-delta, SHIP-1 interactions regulate GPVI-mediated platelet-
RT   dense granule secretion.";
RL   Blood 114:3056-3063(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-218; TYR-313 AND
RP   SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-313 AND SER-664, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF NCF1, AND PHOSPHORYLATION AT THR-507
RP   AND SER-645.
RX   PubMed=19801500; DOI=10.1189/jlb.0408230;
RA   Kilpatrick L.E., Sun S., Li H., Vary T.C., Korchak H.M.;
RT   "Regulation of TNF-induced oxygen radical production in human
RT   neutrophils: role of delta-PKC.";
RL   J. Leukoc. Biol. 87:153-164(2010).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=12473183; DOI=10.1093/oxfordjournals.jbchem.a003294;
RA   Kikkawa U., Matsuzaki H., Yamamoto T.;
RT   "Protein kinase C delta (PKC delta): activation mechanisms and
RT   functions.";
RL   J. Biochem. 132:831-839(2002).
RN   [30]
RP   REVIEW ON FUNCTION.
RX   PubMed=20002545; DOI=10.1111/j.1538-7836.2009.03722.x;
RA   Harper M.T., Poole A.W.;
RT   "Diverse functions of protein kinase C isoforms in platelet activation
RT   and thrombus formation.";
RL   J. Thromb. Haemost. 8:454-462(2010).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-304; TYR-374; SER-645
RP   AND SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [32]
RP   REVIEW ON FUNCTION.
RX   PubMed=21103796; DOI=10.1100/tsw.2010.214;
RA   Basu A., Pal D.;
RT   "Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta
RT   in cell survival and cell death.";
RL   ScientificWorldJournal 10:2272-2284(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=21810427; DOI=10.1016/j.yjmcc.2011.07.013;
RA   Duquesnes N., Lezoualc'h F., Crozatier B.;
RT   "PKC-delta and PKC-epsilon: Foes of the same family or strangers?";
RL   J. Mol. Cell. Cardiol. 51:665-673(2011).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-304 AND SER-645, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [36]
RP   REVIEW.
RX   PubMed=22918451; DOI=10.1007/s00005-012-0188-8;
RA   Zhao M., Xia L., Chen G.Q.;
RT   "Protein kinase cdelta in apoptosis: a brief overview.";
RL   Arch. Immunol. Ther. Exp. 60:361-372(2012).
RN   [37]
RP   INVOLVEMENT IN ALPS3.
RX   PubMed=23319571; DOI=10.1182/blood-2012-10-460741;
RA   Salzer E., Santos-Valente E., Klaver S., Ban S.A., Emminger W.,
RA   Prengemann N.K., Garncarz W., Mullauer L., Kain R., Boztug H.,
RA   Heitger A., Arbeiter K., Eitelberger F., Seidel M.G., Holter W.,
RA   Pollak A., Pickl W.F., Forster-Waldl E., Boztug K.;
RT   "B-cell deficiency and severe autoimmunity caused by deficiency of
RT   protein kinase C delta.";
RL   Blood 121:3112-3116(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-141; SER-299; SER-302;
RP   SER-304; SER-307; SER-503 AND SER-664, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-123 IN COMPLEX WITH
RP   PHOSPHOTYROSINE-CONTAINING PEPTIDE, AND INTERACTION WITH CDCP1.
RX   PubMed=15851033; DOI=10.1016/j.cell.2005.02.019;
RA   Benes C.H., Wu N., Elia A.E.H., Dharia T., Cantley L.C., Soltoff S.P.;
RT   "The C2 domain of PKCdelta is a phosphotyrosine binding domain.";
RL   Cell 121:271-280(2005).
RN   [41]
RP   STRUCTURE BY NMR OF 149-218.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first phorbol esters/diacylglycerol binding
RT   domain of human protein kinase C, delta.";
RL   Submitted (APR-2008) to the PDB data bank.
CC   -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol
CC       (DAG)-dependent serine/threonine-protein kinase that plays
CC       contrasting roles in cell death and cell survival by functioning
CC       as a pro-apoptotic protein during DNA damage-induced apoptosis,
CC       but acting as an anti-apoptotic protein during cytokine receptor-
CC       initiated cell death, is involved in tumor suppression as well as
CC       survival of several cancers, is required for oxygen radical
CC       production by NADPH oxidase and acts as positive or negative
CC       regulator in platelet functional responses. Negatively regulates B
CC       cell proliferation and also has an important function in self-
CC       antigen induced B cell tolerance induction. Upon DNA damage,
CC       activates the promoter of the death-promoting transcription factor
CC       BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription
CC       and apoptosis. In response to oxidative stress, interact with and
CC       activate CHUK/IKKA in the nucleus, causing the phosphorylation of
CC       p53/TP53. In the case of ER stress or DNA damage-induced
CC       apoptosis, can form a complex with the tyrosine-protein kinase
CC       ABL1 which trigger apoptosis independently of p53/TP53. In cytosol
CC       can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting
CC       AKT1 and decreasing the level of X-linked inhibitor of apoptosis
CC       protein (XIAP), whereas in nucleus induces apoptosis via the
CC       activation of MAPK8 or MAPK9. Upon ionizing radiation treatment,
CC       is required for the activation of the apoptosis regulators BAX and
CC       BAK, which trigger the mitochondrial cell death pathway. Can
CC       phosphorylate MCL1 and target it for degradation which is
CC       sufficient to trigger for BAX activation and apoptosis. Is
CC       required for the control of cell cycle progression both at G1/S
CC       and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-
CC       induced inhibition of cell cycle progression at G1/S phase by up-
CC       regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin
CC       CCNA2 promoter activity. In response to UV irradiation can
CC       phosphorylate CDK1, which is important for the G2/M DNA damage
CC       checkpoint activation. Can protect glioma cells from the apoptosis
CC       induced by TNFSF10/TRAIL, probably by inducing increased
CC       phosphorylation and subsequent activation of AKT1. Is highly
CC       expressed in a number of cancer cells and promotes cell survival
CC       and resistance against chemotherapeutic drugs by inducing cyclin
CC       D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-
CC       survival pathways, including NF-kappa-B, AKT1 and MAPK1/3
CC       (ERK1/2). Can also act as tumor suppressor upon mitogenic
CC       stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-
CC       phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-
CC       phox) phosphorylation and activation of NADPH oxidase activity,
CC       and regulates TNF-elicited superoxide anion production in
CC       neutrophils, by direct phosphorylation and activation of NCF1 or
CC       indirectly through MAPK1/3 (ERK1/2) signaling pathways. May also
CC       play a role in the regulation of NADPH oxidase activity in
CC       eosinophil after stimulation with IL5, leukotriene B4 or PMA. In
CC       collagen-induced platelet aggregation, acts a negative regulator
CC       of filopodia formation and actin polymerization by interacting
CC       with and negatively regulating VASP phosphorylation. Downstream of
CC       PAR1, PAR4 and CD36/GP4 receptors, regulates differentially
CC       platelet dense granule secretion; acts as a positive regulator in
CC       PAR-mediated granule secretion, whereas it negatively regulates
CC       CD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-
CC       terminal and regulates the interaction between MUC1 and beta-
CC       catenin. The catalytic subunit phosphorylates 14-3-3 proteins
CC       (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By
CC       similarity). Phosphorylates ELAVL1 in response to angiotensin-2
CC       treatment (PubMed:18285462). {ECO:0000250,
CC       ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,
CC       ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:16940418,
CC       ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,
CC       ECO:0000269|PubMed:19801500}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:18285462}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10027}.
CC   -!- ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are
CC       calcium-insensitive, but activated by diacylglycerol (DAG) and
CC       phosphatidylserine. Three specific sites; Thr-507 (activation loop
CC       of the kinase domain), Ser-645 (turn motif) and Ser-664
CC       (hydrophobic region), need to be phosphorylated for its full
CC       activation. Activated by caspase-3 (CASP3) cleavage during
CC       apoptosis. After cleavage, the pseudosubstrate motif in the
CC       regulatory subunit is released from the substrate recognition site
CC       of the catalytic subunit, which enables PRKCD to become
CC       constitutively activated. The catalytic subunit which displays
CC       properties of a sphingosine-dependent protein kinase is activated
CC       by D-erythro-sphingosine (Sph) or N,N-dimethyl-D-
CC       erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine
CC       (TMS), but not by ceramide or Sph-1-P and is strongly inhibited by
CC       phosphatidylserine (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with PDPK1 (via N-terminal region), RAD9A,
CC       CDCP1, MUC1 and VASP. {ECO:0000269|PubMed:11781095,
CC       ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12628935,
CC       ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418}.
CC   -!- INTERACTION:
CC       Q9BXL7:CARD11; NbExp=7; IntAct=EBI-704279, EBI-7006141;
CC       Q9NR28:DIABLO; NbExp=4; IntAct=EBI-704279, EBI-517508;
CC       P06241:FYN; NbExp=5; IntAct=EBI-704279, EBI-515315;
CC       P17677:GAP43; NbExp=4; IntAct=EBI-704279, EBI-1267511;
CC       C6GKH1:IL32; NbExp=3; IntAct=EBI-704279, EBI-9547476;
CC       P24001-2:IL32; NbExp=7; IntAct=EBI-704279, EBI-8800907;
CC       P19878:NCF2; NbExp=3; IntAct=EBI-704279, EBI-489611;
CC       P11388:TOP2A; NbExp=10; IntAct=EBI-704279, EBI-539628;
CC       P04637:TP53; NbExp=4; IntAct=EBI-704279, EBI-366083;
CC       Q9H3D4:TP63; NbExp=2; IntAct=EBI-704279, EBI-2337775;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}.
CC       Cytoplasm, perinuclear region {ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:17603046}. Nucleus
CC       {ECO:0000269|PubMed:15774464, ECO:0000269|PubMed:17603046,
CC       ECO:0000269|PubMed:18285462}. Cell membrane
CC       {ECO:0000269|PubMed:17603046}; Peripheral membrane protein
CC       {ECO:0000305|PubMed:17603046}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q05655-1; Sequence=Displayed;
CC       Name=2; Synonyms=PKCdeltaVIII;
CC         IsoId=Q05655-2; Sequence=VSP_043899;
CC         Note=Antiapoptotic isoform, resistant to caspase-3 cleavage.;
CC   -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type
CC       region 1 (C1A) and 2 (C1B), is the diacylglycerol sensor.
CC   -!- DOMAIN: The C2 domain is a non-calcium binding domain. It binds
CC       proteins containing phosphotyrosine in a sequence-specific manner.
CC   -!- PTM: Autophosphorylated and/or phosphorylated at Thr-507, within
CC       the activation loop; phosphorylation at Thr-507 is not a
CC       prerequisite for enzymatic activity. Autophosphorylated at Ser-
CC       299, Ser-302 and Ser-304. Upon TNFSF10/TRAIL treatment,
CC       phosphorylated at Tyr-155; phosphorylation is required for its
CC       translocation to the endoplasmic reticulum and cleavage by
CC       caspase-3. Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;
CC       phosphorylation of Tyr-313 and Tyr-567 following thrombin
CC       stimulation potentiates its kinase activity. Phosphorylated by
CC       protein kinase PDPK1; phosphorylation is inhibited by the
CC       apoptotic C-terminal cleavage product of PKN2.
CC       {ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,
CC       ECO:0000269|PubMed:19801500}.
CC   -!- PTM: Proteolytically cleaved into a catalytic subunit and a
CC       regulatory subunit by caspase-3 during apoptosis which results in
CC       kinase activation. {ECO:0000250}.
CC   -!- DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)
CC       [MIM:615559]: A primary immunodeficiency characterized by antibody
CC       deficiency, hypogammaglobulinemia, recurrent bacterial infections
CC       and an inability to mount an antibody response to antigen. The
CC       defect results from a failure of B-cell differentiation and
CC       impaired secretion of immunoglobulins; the numbers of circulating
CC       B-cells is usually in the normal range, but can be low. CVID9
CC       patients have B-cell deficiency and severe autoimmunity.
CC       {ECO:0000269|PubMed:23319571}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07860; AAA03176.1; -; mRNA.
DR   EMBL; L07861; AAA03175.1; -; mRNA.
DR   EMBL; AK313216; BAG36031.1; -; mRNA.
DR   EMBL; CH471055; EAW65279.1; -; Genomic_DNA.
DR   EMBL; BC043350; AAH43350.1; -; mRNA.
DR   EMBL; Z22521; CAA80249.1; -; mRNA.
DR   EMBL; D10495; BAA01381.1; -; mRNA.
DR   EMBL; DQ516383; ABF68960.1; -; mRNA.
DR   CCDS; CCDS2870.1; -. [Q05655-1]
DR   PIR; S35704; S35704.
DR   RefSeq; NP_001303256.1; NM_001316327.1. [Q05655-1]
DR   RefSeq; NP_006245.2; NM_006254.3. [Q05655-1]
DR   RefSeq; NP_997704.1; NM_212539.1. [Q05655-1]
DR   RefSeq; XP_006713322.1; XM_006713259.2. [Q05655-1]
DR   RefSeq; XP_016862344.1; XM_017006855.1. [Q05655-1]
DR   RefSeq; XP_016862345.1; XM_017006856.1. [Q05655-1]
DR   UniGene; Hs.155342; -.
DR   PDB; 1YRK; X-ray; 1.70 A; A=1-123.
DR   PDB; 2YUU; NMR; -; A=149-218.
DR   PDBsum; 1YRK; -.
DR   PDBsum; 2YUU; -.
DR   ProteinModelPortal; Q05655; -.
DR   SMR; Q05655; -.
DR   BioGrid; 111566; 94.
DR   DIP; DIP-29954N; -.
DR   IntAct; Q05655; 48.
DR   MINT; MINT-1346366; -.
DR   STRING; 9606.ENSP00000331602; -.
DR   BindingDB; Q05655; -.
DR   ChEMBL; CHEMBL2996; -.
DR   DrugBank; DB04376; 13-Acetylphorbol.
DR   DrugBank; DB05013; Ingenol Mebutate.
DR   DrugBank; DB00675; Tamoxifen.
DR   GuidetoPHARMACOLOGY; 1485; -.
DR   iPTMnet; Q05655; -.
DR   PhosphoSitePlus; Q05655; -.
DR   BioMuta; PRKCD; -.
DR   DMDM; 205371776; -.
DR   EPD; Q05655; -.
DR   MaxQB; Q05655; -.
DR   PaxDb; Q05655; -.
DR   PeptideAtlas; Q05655; -.
DR   PRIDE; Q05655; -.
DR   DNASU; 5580; -.
DR   Ensembl; ENST00000330452; ENSP00000331602; ENSG00000163932. [Q05655-1]
DR   Ensembl; ENST00000394729; ENSP00000378217; ENSG00000163932. [Q05655-1]
DR   GeneID; 5580; -.
DR   KEGG; hsa:5580; -.
DR   UCSC; uc003dgl.4; human. [Q05655-1]
DR   CTD; 5580; -.
DR   DisGeNET; 5580; -.
DR   GeneCards; PRKCD; -.
DR   HGNC; HGNC:9399; PRKCD.
DR   HPA; CAB010469; -.
DR   HPA; CAB013225; -.
DR   HPA; HPA001863; -.
DR   HPA; HPA001890; -.
DR   MalaCards; PRKCD; -.
DR   MIM; 176977; gene.
DR   MIM; 615559; phenotype.
DR   neXtProt; NX_Q05655; -.
DR   OpenTargets; ENSG00000163932; -.
DR   Orphanet; 3261; Autoimmune lymphoproliferative syndrome.
DR   Orphanet; 300345; Autosomal recessive systemic lupus erythematosus.
DR   Orphanet; 1572; Common variable immunodeficiency.
DR   PharmGKB; PA33763; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOGENOM; HOG000233022; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; Q05655; -.
DR   KO; K06068; -.
DR   OMA; GEDEAKF; -.
DR   OrthoDB; EOG091G0QRS; -.
DR   PhylomeDB; Q05655; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-111933; Calmodulin induced events.
DR   Reactome; R-HSA-114508; Effects of PIP2 hydrolysis.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1489509; DAG and IP3 signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   SABIO-RK; Q05655; -.
DR   SignaLink; Q05655; -.
DR   SIGNOR; Q05655; -.
DR   ChiTaRS; PRKCD; human.
DR   EvolutionaryTrace; Q05655; -.
DR   GeneWiki; PRKCD; -.
DR   GenomeRNAi; 5580; -.
DR   PMAP-CutDB; Q05655; -.
DR   PRO; PR:Q05655; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000163932; -.
DR   CleanEx; HS_PRKCD; -.
DR   ExpressionAtlas; Q05655; baseline and differential.
DR   Genevisible; Q05655; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004699; F:calcium-independent protein kinase C activity; EXP:Reactome.
DR   GO; GO:0008047; F:enzyme activator activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IDA:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:BHF-UCL.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004697; F:protein kinase C activity; ISS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:Reactome.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:1904385; P:cellular response to angiotensin; IDA:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0071447; P:cellular response to hydroperoxide; IDA:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0097194; P:execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0016572; P:histone phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; IEA:Ensembl.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0032613; P:interleukin-10 production; IEA:Ensembl.
DR   GO; GO:0032615; P:interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0030837; P:negative regulation of actin filament polymerization; ISS:UniProtKB.
DR   GO; GO:0051490; P:negative regulation of filopodium assembly; ISS:UniProtKB.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0090331; P:negative regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; TAS:BHF-UCL.
DR   GO; GO:0042119; P:neutrophil activation; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:2000304; P:positive regulation of ceramide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IMP:UniProtKB.
DR   GO; GO:2000753; P:positive regulation of glucosylceramide catabolic process; IMP:BHF-UCL.
DR   GO; GO:1900163; P:positive regulation of phospholipid scramblase activity; IMP:UniProtKB.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IMP:BHF-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:2001022; P:positive regulation of response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:2000755; P:positive regulation of sphingomyelin catabolic process; IMP:BHF-UCL.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; NAS:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:CACAO.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0010469; P:regulation of receptor activity; TAS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:Reactome.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0023021; P:termination of signal transduction; IMP:BHF-UCL.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05620; STKc_nPKC_delta; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR034667; nPKC_delta.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR027436; PKC_delta.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR014376; Prot_kin_PKC_delta.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000551; PKC_delta; 1.
DR   PIRSF; PIRSF501104; Protein_kin_C_delta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell cycle; Cell membrane; Complete proteome; Cytoplasm; Kinase;
KW   Membrane; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Tumor suppressor; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    676       Protein kinase C delta type.
FT                                /FTId=PRO_0000055694.
FT   CHAIN         1    329       Protein kinase C delta type regulatory
FT                                subunit. {ECO:0000250}.
FT                                /FTId=PRO_0000421667.
FT   CHAIN       330    676       Protein kinase C delta type catalytic
FT                                subunit. {ECO:0000250}.
FT                                /FTId=PRO_0000421668.
FT   DOMAIN        1     90       C2.
FT   DOMAIN      349    603       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      604    675       AGC-kinase C-terminal.
FT   ZN_FING     158    208       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     230    280       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     355    363       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    473    473       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     378    378       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         48     48       Interaction with phosphotyrosine-
FT                                containing peptide.
FT   SITE         62     62       Interaction with phosphotyrosine-
FT                                containing peptide.
FT   SITE         67     67       Interaction with phosphotyrosine-
FT                                containing peptide.
FT   SITE        123    123       Interaction with phosphotyrosine-
FT                                containing peptide.
FT   SITE        329    330       Cleavage; by caspase-3. {ECO:0000250}.
FT   MOD_RES      43     43       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P28867}.
FT   MOD_RES      50     50       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17965192}.
FT   MOD_RES      64     64       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P09215}.
FT   MOD_RES     130    130       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     141    141       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17965192}.
FT   MOD_RES     155    155       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15774464}.
FT   MOD_RES     218    218       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     299    299       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17603046}.
FT   MOD_RES     302    302       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17603046}.
FT   MOD_RES     304    304       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17603046,
FT                                ECO:0000269|PubMed:17965192}.
FT   MOD_RES     307    307       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     313    313       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:17570831}.
FT   MOD_RES     334    334       Phosphotyrosine; by SRC.
FT                                {ECO:0000305|PubMed:11781095}.
FT   MOD_RES     374    374       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     451    451       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17965192}.
FT   MOD_RES     503    503       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     506    506       Phosphoserine.
FT                                {ECO:0000269|PubMed:17965192}.
FT   MOD_RES     507    507       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17965192,
FT                                ECO:0000305|PubMed:19801500}.
FT   MOD_RES     567    567       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17570831}.
FT   MOD_RES     645    645       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:19801500}.
FT   MOD_RES     654    654       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     658    658       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     664    664       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:17965192}.
FT   VAR_SEQ     328    328       Q -> QGEAGSIAPLRFLFPLRPKKGDCPPFHCQVRQ (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:18092819}.
FT                                /FTId=VSP_043899.
FT   VARIANT     348    348       N -> S (in dbSNP:rs33911937).
FT                                /FTId=VAR_035347.
FT   VARIANT     375    375       F -> S (in dbSNP:rs1056998).
FT                                {ECO:0000269|PubMed:8357834}.
FT                                /FTId=VAR_006175.
FT   VARIANT     410    410       L -> F (in dbSNP:rs34502209).
FT                                /FTId=VAR_035348.
FT   VARIANT     483    483       R -> W (in dbSNP:rs35891605).
FT                                /FTId=VAR_046009.
FT   VARIANT     494    494       M -> V. {ECO:0000269|PubMed:7988719}.
FT                                /FTId=VAR_020610.
FT   VARIANT     593    593       V -> M. {ECO:0000269|PubMed:8357834}.
FT                                /FTId=VAR_006176.
FT   MUTAGEN     299    299       S->A: Loss of phosphorylation.
FT                                {ECO:0000269|PubMed:17603046}.
FT   MUTAGEN     507    507       T->A: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:11772397}.
FT   CONFLICT    524    524       K -> R (in Ref. 2; BAG36031).
FT                                {ECO:0000305}.
FT   CONFLICT    533    533       S -> A (in Ref. 8; no nucleotide entry).
FT                                {ECO:0000305}.
FT   STRAND        1     13       {ECO:0000244|PDB:1YRK}.
FT   STRAND       20     23       {ECO:0000244|PDB:1YRK}.
FT   STRAND       27     38       {ECO:0000244|PDB:1YRK}.
FT   STRAND       41     45       {ECO:0000244|PDB:1YRK}.
FT   STRAND       58     62       {ECO:0000244|PDB:1YRK}.
FT   STRAND       68     76       {ECO:0000244|PDB:1YRK}.
FT   STRAND       79     87       {ECO:0000244|PDB:1YRK}.
FT   HELIX        88     96       {ECO:0000244|PDB:1YRK}.
FT   TURN         97    100       {ECO:0000244|PDB:1YRK}.
FT   STRAND      101    107       {ECO:0000244|PDB:1YRK}.
FT   STRAND      109    111       {ECO:0000244|PDB:1YRK}.
FT   STRAND      113    123       {ECO:0000244|PDB:1YRK}.
FT   HELIX       156    158       {ECO:0000244|PDB:2YUU}.
FT   STRAND      161    164       {ECO:0000244|PDB:2YUU}.
FT   STRAND      173    175       {ECO:0000244|PDB:2YUU}.
FT   STRAND      181    183       {ECO:0000244|PDB:2YUU}.
FT   STRAND      186    189       {ECO:0000244|PDB:2YUU}.
FT   TURN        190    192       {ECO:0000244|PDB:2YUU}.
FT   HELIX       200    202       {ECO:0000244|PDB:2YUU}.
SQ   SEQUENCE   676 AA;  77505 MW;  013F4314A2EE331A CRC64;
     MAPFLRIAFN SYELGSLQAE DEANQPFCAV KMKEALSTER GKTLVQKKPT MYPEWKSTFD
     AHIYEGRVIQ IVLMRAAEEP VSEVTVGVSV LAERCKKNNG KAEFWLDLQP QAKVLMSVQY
     FLEDVDCKQS MRSEDEAKFP TMNRRGAIKQ AKIHYIKNHE FIATFFGQPT FCSVCKDFVW
     GLNKQGYKCR QCNAAIHKKC IDKIIGRCTG TAANSRDTIF QKERFNIDMP HRFKVHNYMS
     PTFCDHCGSL LWGLVKQGLK CEDCGMNVHH KCREKVANLC GINQKLLAEA LNQVTQRASR
     RSDSASSEPV GIYQGFEKKT GVAGEDMQDN SGTYGKIWEG SSKCNINNFI FHKVLGKGSF
     GKVLLGELKG RGEYFAIKAL KKDVVLIDDD VECTMVEKRV LTLAAENPFL THLICTFQTK
     DHLFFVMEFL NGGDLMYHIQ DKGRFELYRA TFYAAEIMCG LQFLHSKGII YRDLKLDNVL
     LDRDGHIKIA DFGMCKENIF GESRASTFCG TPDYIAPEIL QGLKYTFSVD WWSFGVLLYE
     MLIGQSPFHG DDEDELFESI RVDTPHYPRW ITKESKDILE KLFEREPTKR LGVTGNIKIH
     PFFKTINWTL LEKRRLEPPF RPKVKSPRDY SNFDQEFLNE KARLSYSDKN LIDSMDQSAF
     AGFSFVNPKF EHLLED
//
